Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other Working Capital Changes (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Other Working Capital Changes for 10 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes rose 918.59% to $2.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.0 million through Dec 2025, up 183.33% year-over-year, with the annual reading at $10.0 million for FY2025, 183.33% up from the prior year.
  • Other Working Capital Changes for Q4 2025 was $2.7 million at Ultragenyx Pharmaceutical, up from -$9.9 million in the prior quarter.
  • The five-year high for Other Working Capital Changes was $22.5 million in Q4 2021, with the low at -$12.7 million in Q3 2024.
  • Average Other Working Capital Changes over 5 years is $543450.0, with a median of -$697000.0 recorded in 2022.
  • The sharpest move saw Other Working Capital Changes skyrocketed 1062.45% in 2022, then crashed 1362.62% in 2024.
  • Over 5 years, Other Working Capital Changes stood at $22.5 million in 2021, then tumbled by 104.8% to -$1.1 million in 2022, then skyrocketed by 246.53% to $1.6 million in 2023, then plummeted by 83.02% to $269000.0 in 2024, then soared by 918.59% to $2.7 million in 2025.
  • According to Business Quant data, Other Working Capital Changes over the past three periods came in at $2.7 million, -$9.9 million, and -$313000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.